natgillin/translations-raw huggingface dataset:
NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 6 mg hard capsules 
RAVIMPREPARAADI NIMETUS Rivastigmine Teva 6 mg kõvakapslid
Flesh colour cap imprinted with “R” & flesh color body imprinted with “3” 
Kollakasroosat värvi kaas, millele on trükitud “R” ja kollakasroosat värvi keha, millele on trükitud “3”
Adjusted treatment difference n/a p-value versus placebo 
Keskmine muutus 24. nädalal ± SH Kohandatud ravierinevus n/a p-väärtus vs platseebo
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton - Rivastigmine Teva 4.5 mg hard capsules 
VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp - Rivastigmine Teva 4,5 mg kõvakapslid
• Difficulty in sleeping 
• raske segasusseisund
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton - Rivastigmine Teva 3 mg hard capsules 
VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Karp - Rivastigmine Teva 3 mg kõvakapslid
Your doctor will tell you whether your illness allows you to drive vehicles and use machines safely.. Rivastigmine Teva may cause dizziness and somnolence, mainly at the start of treatment or when increasing the dose.If you feel dizzy or sleepy do not drive, use machines or perform any tasks that require your attention. 
Arst ütleb teile, kas teie haigus võimaldab teil ohutult autot juhtida ja masinatega töötada.
- if you have, or have ever had, an active stomach ulcer. 
- kui teil on või on kunagi olnudaktiivne maohaavand.
NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 1.5 mg hard capsules Rivastigmine 
RAVIMPREPARAADI NIMETUS Rivastigmine Teva 1,5 mg kõvakapslid Rivastigminum
Cardiac disorders Common 
Südame häired Harv
QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 1.5 mg For a full list of excipients, see section 6.1. 
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 1,5 mg rivastigmiinile.
NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 3 mg hard capsules Rivastigmine 
RAVIMPREPARAADI NIMETUS Rivastigmine Teva 3 mg kõvakapslid Rivastigminum
NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 3 mg hard capsules 
RAVIMPREPARAADI NIMETUS Rivastigmine Teva 3 mg kõvakapslid
NAME OF THE MEDICINAL PRODUCT Rivastigmine Teva 6 mg hard capsules Rivastigmine 
RAVIMPREPARAADI NIMETUS Rivastigmine Teva 6 mg kõvakapslid Rivastigminum
QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 4.5 mg For a full list of excipients, see section 6.1. 
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 4,5 mg rivastigmiinile.
Anxiety 
Agitatsioon
Capsule shell Red iron oxide (E172) Yellow iron oxide (E172) 
Kollane raudoksiid (E172)
QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 6 mg For a full list of excipients, see section 6.1. 
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 6 mg rivastigmiinile.
Gastrointestinal haemorrhage 
Lihas-skeleti jäikus
Teva Nederland B.V. Tel: +31 (0) 800 0228400 
Teva Pharmaceuticals Ireland Tel: +353 (0)42 9395 892
Suomi/Finland ratiopharm Oy 
België/Belgique/Belgien
QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains rivastigmine hydrogen tartrate corresponding to rivastigmine 3 mg For a full list of excipients, see section 6.1. 
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks kapsel sisaldab rivastigmiinvesiniktartraati koguses, mis vastab 3 mg rivastigmiinile.
BATCH NUMBER BN 
PARTII NUMBER Partii nr:
- HDPE tablet container with a polypropylene cap and induction seal: 250 capsules 
RAVIMVORM JA PAKENDI SUURUS 250 kõvakapslit
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister - Rivastigmine Teva 4.5 mg hard capsules 
Blister - Rivastigmine Teva 4,5 mg kõvakapslid
Treatment 
Raviannuse määramine
Subjects with hepatic impairment 
• südame rütmihäired
Sutent sunitinib 
Sutent sunitiniib
What measures are being taken to ensure the safe and effective use of Sutent? 
Mis meetmed võetakse, et tagada Sutenti ohutu ja efektiivne kasutamine?
A risk management plan has been developed to ensure that Sutent is used as safely as possible. 
Töötati välja riskijuhtimiskava, et tagada Sutenti võimalikult ohutu kasutamine.
The full EPAR for Sutent can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Euroopa avaliku hindamisaruande täistekst Sutenti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
It is available as capsules (12.5 mg, 25 mg, 37.5 mg and 50 mg). 
Ravimit turustatakse kapslitena (12,5 mg, 25 mg, 37,5 mg ja 50 mg).
This dose may also be adjusted. 
Annust võib olla vaja kohandada.
The European Commission granted a conditional marketing authorisation valid throughout the European Union for Sutent on 19 July 2006. 
Euroopa Komisjon andis Sutenti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. juulil 2006.
This was switched to a full marketing authorisation on 11 January 2007. 
Tingimuslik müügiluba muudeti tavaliseks müügiloaks 11. jaanuaril 2007.
The most common side effects with Sutent (seen in more than 1 in 10 patients) include fatigue (tiredness), gastrointestinal disorders (such as diarrhoea, feeling sick, inflammation of the lining of the mouth, indigestion and vomiting), respiratory (such as shortness of breath and cough) and skin disorders (such as skin discoloration, dryness of the skin and rash), hair color changes, dysgeusia (taste disturbances), epistaxis (nosebleeds), loss of appetite, hypertension (high blood pressure), palmar-plantar erythrodysaesthesia syndrome (rash and numbness on the palms and soles), hypothyroidism (an underactive thyroid gland), insomnia (difficulty falling and staying asleep), dizziness, headache, arthralgia (joint pain), neutropenia (low levels of neutrophils, a type of white blood cell), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), and leucopenia (low white blood cell counts). 
Sutenti kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on väsimus, seedetrakti häired (nagu kõhulahtisus, iiveldus, suu limaskesta põletik, seedehäired ja oksendamine), hingamishäired (nt raskendatud hingamine ja köha) ja nahahäired (nt nahavärvuse muutus, nahakuivus ja lööve), juuksevärvuse muutus, düsgeusia (maitsehäired), epistaksis (ninaverejooks), isutus, hüpertensioon (kõrgvererõhutõbi), palmaar-plantaarne erütrodüsesteesia (käe- ja jalalabade lööve ja tuimus), hüpotüroidism (kilpnäärme alatalitlus), unetus (uinumis- ja unehäired), peapööritus, peavalu, liigesevalu, neutropeenia (teatud valgeliblede neutrofiilide vähesus), trombotsütopeenia (vereliistakute vähesus), aneemia (erütrotsüütide ehk vere punaliblede vähesus) ja leukopeenia (leukotsüütide ehk vere valgeliblede vähesus).
Other information about Sutent 
Muu teave Sutenti kohta
Sutent is used if the disease is getting worse and the tumour cells are well-differentiated (similar to normal cells in the pancreas). 
Sutenti kasutatakse, kui haigus süveneb ja kasvajarakud on hästi diferentseerunud (sarnanevad kõhunäärme normaalsete rakkudega).
This is a summary of the European public assessment report (EPAR) for Sutent. 
See on ravimi Sutent Euroopa avaliku hindamisaruande kokkuvõte.
The CHMP decided that Sutent's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Inimravimite komitee otsustas, et Sutenti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
For more information about treatment with Sutent, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Sutentiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Sutent is a medicine that contains the active substance sunitinib. 
Sutent on ravim, mis sisaldab toimeainena sunitiniibi.
Why has Sutent been approved? 
Miks Sutent heaks kiideti?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Sutent, including the appropriate precautions to be followed by healthcare professionals and patients. 
Selle alusel lisati Sutenti omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
The dose can be adjusted according to the patient's response to the treatment, but should be kept within the range of 25 to 75 mg. For pancreatic neuroendocrine tumours, Sutent is given at a dose of 37.5 mg once a day without a rest period. 
Patsiendi ravivastuse järgi tohib annust kohandada , kuid see peab olema vahemikus 25-75 mg. Pankrease neuroendokriintuumorite korral antakse Sutenti annuses 37,5 mg üks kord ööpäevas ilma pausita.
Sutent was also compared with another cancer medicine, interferon alfa, in 750 patients with metastatic renal cell carcinoma whose cancer had not been treated before. 
Sutenti võrreldi ka vähiravimi alfainterferooniga uuringus, milles osales 750 metastaatilise neerurakk-kartsinoomiga patsienti, kelle vähki ei olnud varem ravitud.
Sutent is used to treat adults with the following types of cancer: 
Sutenti kasutatakse täiskasvanud patsientidel järgmiste vähivormide raviks:
For the full list of all side effects and restrictions with Sutent, see the package leaflet. 
Sutenti kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sutent. 
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
The main measure of effectiveness in all of the studies was how long the patients lived without their tumours getting worse. 
Kõigis uuringutes oli efektiivsuse põhinäitaja aeg haiguse süvenemiseni.
Sutent was compared with placebo (a dummy treatment) in 312 patients with GIST whose previous treatment with imatinib had failed and in 171 patients with worsening pancreatic neuroendocrine tumours that could not be removed with surgery. 
Sutenti võrreldi platseeboga (näiv ravim) 312 gastrointestinaalse stromaaltuumoriga patsiendil, kelle varasem ravi imatiniibiga oli ebaõnnestunud, ja 171 pankrease kaugelearenenud neuroendokriintuumoriga patsiendil, mida ei olnud võimalik kirurgiliselt eemaldada.
For GIST and metastatic renal cell carcinoma, Sutent is given in six-week cycles, at a dose of 50 mg once a day for four weeks, followed by a two-week ‘rest period'. 
Gastrointestinaalse stromaaltuumori ja metastaatilise neerurakk-kartsinoomi korral antakse Sutenti 6nädalaste tsüklitena: 50 mg ööpäevase annusena nelja nädala jooksul, millele järgneb kahenädalane paus.
The most serious side effects reported with Sutent include heart and kidney failure, pulmonary embolism (clot in a blood vessel supplying the lungs), gastrointestinal perforation (holes in the wall of the gut), and internal haemorrhages (bleeding). 
Sutenti kõige raskemate kõrvalnähtude hulka kuuluvad südame- ja neerupuudulikkus, kopsuemboolia (trombid kopsudes), seedekulgla perforatsioonid (soolemulgustused) ja sisemised verejooksud.
What is the risk associated with Sutent? 
Mis riskid Sutentiga kaasnevad?
By blocking these enzymes, Sutent can reduce the growth and spread of the cancer and cut off the blood supply that keeps cancer cells growing. 
Neid ensüüme blokeerides takistab Sutent vähi kasvu ja levikut ning peatab vähirakkude kasvu toetava verevarustuse.
Sutent was originally given ‘conditional approval' because there was more evidence to come about the medicine, in particular in the treatment of renal cell carcinoma. 
Sutentile anti müügiluba esialgu tingimuslikult, sest ravimi ja eelkõige selle kasutamise kohta neerurakk-kartsinoomi ravis oodati täiendavaid andmeid.
What benefit has Sutent shown during the studies? 
Milles seisneb uuringute põhjal Sutenti kasulikkus?
• pancreatic neuroendocrine tumours (tumours of the hormone-producing cells in the pancreas) that have spread or cannot be removed with surgery. 
• pankrease neuroendokriintuumorid (kõhunäärme hormoone tekitavate rakkude kasvajad), mis on levinud organismis ka mujale või mida ei saa kirurgiliselt eemaldada.
These enzymes can be found in some receptors at the surface of cancer cells, where they are involved in the growth and spread of cancer cells and in the blood vessels that supply the tumours, where they are involved in the development of new blood vessels. 
Neid leidub teatud retseptorites vähirakkude pinnal, kus osalevad vähirakkude kasvus ja levikus, ning kasvajaid varustavates veresoontes, kus osalevad uute veresoonte tekkes.
Treatment with Sutent should be started by doctors who have experience in administering cancer medicines. 
Ravi Sutentiga peab alustama vähiravimite manustamises kogenud arst.
It is used after treatment with imatinib (another cancer medicine) has failed; 
Ravimit kasutatakse pärast seda, kui ravi vähiravimi imatiniibiga on ebaõnnestunud;
• metastatic renal cell carcinoma, a type of kidney cancer, that has spread to other parts of the body; 
• metastaatiline neerurakk-kartsinoom - teatud liiki neeruvähk, mis on levinud organismis ka mujale;
• gastrointestinal stromal tumour (GIST), a type of cancer of the stomach and bowel where there is uncontrolled growth of cells in the supporting tissues of these organs. 
• gastrointestinaalne stromaaltuumor (GIST) - teatud liiki mao- ja soolevähk, mille korral nende elundite tugikudede rakud hakkavad takistamatult vohama.
The active substance in Sutent, sunitinib, is a protein kinase inhibitor. 
Sutenti toimeaine sunitiniib on proteiinkinaasiinhibiitor ehk aine, mis blokeerib teatud ensüüme proteiinkinaase.
Sutent is used in patients with GISTs that cannot be removed with surgery or have spread to other parts of the body. 
Sutenti kasutatakse gastrointestinaalsete stromaaltuumoritega täiskasvanute raviks, kui neid tuumoreid ei saa kirurgiliselt eemaldada või kui vähk on levinud organismis ka mujale.
What is Sutent used for? 
Milleks Sutenti kasutatakse?
In metastatic renal cell carcinoma, patients taking Sutent lived for an average of 47.3 weeks without their disease worsening, compared with 22.0 weeks in the patients receiving interferon alfa. 
Metastaatilise neerurakk-kartsinoomi korral oli aeg haiguse süvenemiseni Sutenti saanute rühmas keskmiselt 47,3 nädalat ja alfainterferooni rühmas 22,0 nädalat.
Sutent was more effective than placebo in treating GIST and pancreatic neuroendocrine tumours. 
Sutent oli gastrointestinaalse stromaaltuumori ja pankrease neuroendokriintuumorite ravis platseebost efektiivsem.
How is Sutent used? 
Kuidas Sutenti kasutatakse?
Patients with GIST taking Sutent lived for an average of 26.6 weeks without the disease getting worse, compared with 6.4 weeks in the patients taking placebo. 
Gastrointestinaalse stromaaltuumori korral oli progresseerumiseta elulemus Sutenti saanud patsientidel keskmiselt 26,6 nädalat ja platseebot saanutel 6,4 nädalat.
For pancreatic neuroendocrine tumours the figures were 11.4 months in the Sutent group and 5.5 months in the placebo group. 
Pankrease neuroendokriintuumorite korral oli haiguse süvenemiseni kulunud aeg Sutenti saanud patsientidel keskmiselt 11,4 kuud ja platseebot saanud patsientidel 5,5 kuud.
How has Sutent been studied? 
Kuidas Sutenti uuriti?
The medicine can only be obtained with a prescription. 
Sutent on retseptiravim.
EU number 
Müügilo nr Euroopa Liidus
83607 Holzkirchen Germany 
25, 83607 Holzkirchen Saksamaa
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF SANOHEX AND ASSOCIATED NAMES (SEE ANNEX I) 
SANOHEXI JA SELLEGA SEOTUD NIMETUSTE (VT I LISA) TEADUSLIKU HINDAMISE ÜLDKOKKUVÕTE
The Applicant also decided to generate additional spacer data in order to obtain more reliable information on the particle size distribution when the compared inhalers are fitted with their respective spacer devices. 
Taotleja otsustas esitada ka täiendavad vahemahutiga saadud andmed, et saada usaldusväärsemat teavet osakeste suurusjaotuse kohta, kui võrreldavate inhalaatorite külge on kinnitatud neile sobiv vahemahuti.
the CHMP has recommended the granting of the Marketing Authorisations for which the valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure are set out in Annex III for Sanohex and associated names (see Annex I). 
on komitee soovitanud müügilubade andmist, milles kehtiv ravimi omaduste kokkuvõte, märgistus ja pakendi infoleht on lõplikud versioonid, mis saavutati koordineerimisrühma menetlusega ning mis on esitatud Sanohexi ja sarnaste nimetuste puhul III lisas (vt I lisa).
Sanohex is a metered dose aerosol inhaler containing a suspension formulation of salbutamol sulphate 100 µg/spray, with HFA 134a as propellant. 
Selles on suspensioon, mis sisaldab salbutamoolsulfaati annuses 100 µg pihustuse kohta ja propellendiks on HFA 134a.
- the CHMP considered that Sanohex and the reference product possess the same systemic safety profile, as demonstrated by the bioequivalence in systemic levels (AUC and Cmax), 
- komitee leidis, et Sanohexil ja võrdlusravimil on samasugune süsteemne ohutusprofiil, mida näidati bioekvivalentsuse alusel süsteemsetel tasemetel (AUC ja Cmax),
The marketing applications were submitted as hybrid applications under Article 10(3) of Directive 2001/83/EC and the EU reference product is Sultanol Dosier-Aerosol 100 μg/dose, Druckgasinhalation, suspension, (GlaxoSmithKline). 
Euroopa Liidus on võrdlusravimiks Sultanol Dosier-Aerosol 100 μg annuses, Druckgasinhalation, suspensioon (GlaxoSmithKline).
The pharmacokinetic bioequivalence data also confirmed that Sanohex and the reference product possess the same systemic safety profile since bioequivalence in systemic levels (AUC and Cmax) have been shown, when used with or without a spacer. 
Farmakokineetilise bioekvivalentsuse andmed kinnitasid samuti, et Sanohexil ja võrdlusravimil on samasugune süsteemne ohutusprofiil, sest bioekvivalentsust näidati süsteemsetel tasemetel (AUC ja Cmax) nii vahemahutiga kui ka ilma.
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states 
Ravimi nimetuste nimekiri, ravimvorm, ravimpreparaadi tugevus, manustamisviis, müügiloa hoidjad liikmesriikides liikmesriik Müügiloa hoidja
164 94 Kista 
164 94 Kista Sweden
Hungary Baxter Hungary Kft. Népfürdő u. 22. 
Baxter Hungary Kft. Népfürdö u. 22.
Sweden Baxter Medical AB Box 63 
Baxter Medical AB Box 63
Germany Baxter Deutschland GmbH Edisonstr. 
Saksamaa Baxter Deutschland GmbH Edisonstr.
Kifissias Avenue 368, Halandri, 152 33 Greece 
Diophar SA Kifissias 368 Halandri 15233 Greece
Baxter MédicoFarmacêutica, Lda. 
Baxter Médico Farmacêutica Lda
Baxter SPA piazzale dell' industria 20 - 00144 Roma, Italy 
Piazzale dell'Industria 20 00144 Roma Italy
11 g/l amino acids and 1,25 mmol/l Ca. 
11 g/l Aminohapped ja 1,25 mmol/l Ca.
Romania BAXTER d.o.o. 
Rumeenia BAXTER d.o.o.
Slovak Republic 
Slovaki Vabariigi
Belgium Baxter SA Boulevard R. Branquart 80 7680 Lessines Belgium 
Boulevard R. Branquart 80 7680 Lessines Belgium
Denmark Baxter A/S, Gydevang 43, DK-3450 Allerød 
Baxter A/S Gydevang 43 3450 Allerød Denmark
Luxembourg Baxter SA, Bd René Branquart 80, B-7860 Lessines Belgium 
Luksemburg Baxter S.A. Bd René Branquart 80 B-7860 Lessines Belgium
Norfolk IP24 3SE United Kingdom 
Thetford IP24 3SE United Kingdom
Box 270 Valimotie 15A 00381 
Box 270 Valimotie 15A 00381 Helsinki Finland
Avenue louis Pasteur ZA de Coignières Maurepas 78310 Maurepas France 
Prantsusmaa Baxter S.A.S Avenue louis Pasteur 78310 ZA de Coigneres 78310 Maurepas France
Zelezna cesta 14, SI-1000 Ljubljana 
Zelezna cesta 14, SI-1000 Ljubljana, Slovenia
Nutrineal PD4 met 11 g/l aminozuren en Ca 1,25 mmol/l, peritoneaaldialysevloeistof 
Nutrineal PD4 met 11 g/l aminozuren en Ca 1,25 mmol/l, peritoneaaldialysevloeis t of
7,5% (icodextrin) 
7,5% (Ikodekstriin)
4.480 g, Sodium chloride Ph. Eur. 
4.480 g, Naatriumkloriid Ph. Eur.
0.152, Sodium Lactate Ph. Eur. 
0.152, Naatriumlaktaat Ph. Eur.
0.0257 % w/v, Magnesium Chloride Ph. Eur. 
0.0257 % w/v, magneesiumkloriid Ph. Eur.
Glucose Monohydrate Ph. Eur.1.1, Sodium Chloride Ph. Eur. 
Glükoosmonohüdraat Ph. Eur.1.1, Naatriumkloriid Ph. Eur.
Natriumklorid Baxter 9 mg/ml solution for infusion intravenous use 
Natriumklorid Baxter 9 mg/ml
L-Tyrosine Ph.Eur. 
L-Türosiin Ph.Eur.
Netherlands Baxter B.V., Kobaltweg 49, 3542 CE Utrecht 
Holland Baxter B.V Kobaltweg 49
BAXTER S.L. 
Baxter S.A.
Zona Industrial da Abrunheira - Edifício 10Sintra Business Park, 2710-089 Sintra Portugal 
Edificio 10 Sintra Business Park,
1.071 g, Calcium chloride dihydrate Ph.Eur. 
1.071 g, kaltsiumkloriid dihüdraat Ph.Eur.
75.00 g/l Icodextrine 
75.00 g/l Ikodekstriin
1.1, Sodium Chloride Ph. Eur. 
1.1, Naatriumkloriid Ph. Eur.
0.54 % w/v, Sodium (S)-lactate 0.45 % w/v, Calcium Chloride Ph. Eur. 
0.54 % w/v, naatrium (S)-laktaat 0.45 % w/v, kaltsiumkloriid Ph. Eur.
0.184 g, Magnesium chloride hexahydrate Ph.Eur. 
0.184 g, Magneesiumkloriidheksahüdraat Ph.Eur.
Extraneal (Icodextrin 7.5%) Solution for peritoneal dialysis icodextrin 75g/l; sodium chloride 5.4g/l; calcium chloride 0,257g/l; magnesium chloride 0.051g/l; sodium s-lactate 4.5g/l 
Extraneal (lcodextrin 7.5%) Solution for peritoneal dialysis ikodekstriin 75g/l; naatriumkloriid 5.4g/l; kaltsiumkloriid 0,257g/l; magneesiumkloriid 0.051g/l; naatrium s-laktaat 4.5g/l
7,5 % 75 g / 1000 ml peritoneal use 
7,5 % 75g/1000 ml
Sodium Hydroxide 52.25 g Water for Injections to 100 ml 
Piimhape 139 g Naatriumhüdroksiid 52.25 g Süstevesi kuni 100 ml
75 g/l icodextrine 
75 g/l Ikodekstriin
Lithuania Baxter Oy, P.O. 
Baxter Oy P.O.
6.43, Calcium Chloride Dihydrate Ph. 
6.43, Kaltsiumkloriiddihüdraat Ph.
Baxter Healthcare S.A. Moneen Road Castlebar 
Baxter Healthcare SA Moneen Road Castlebar
Slovenia Baxter d.o.o., Zelezna cesta 18 , Ljubljana, SI-1000, Slovenia 
Sloveenia Baxter d.o.o., Zelezna cesta 18 ,Ljubljana, SI-1000, Slovenia
Icodextrin 7.5 % w/v, Sodium Chloride Ph. 
Ikodekstriin 7.5 % w/v, naatriumkloriid Ph. Eur.
0.951 g, L-Valine Ph.Eur. 
0.951 g, L-Valiin Ph.Eur.
0.646 g, L-Serine Ph.Eur. 
0.646 g, L-Seriin Ph.Eur.
3.36, Potassium Chloride Ph. Eur. 
3.36, Kaaliumkloriid Ph. Eur.
Nutrineal PD4 with 1.1% Amino Acids tyrosine 0.03%w/v; tryptophan 0.027%w/v; phenylalanine 0.057%w/v; threonine 0.064%w/v; L-serine 0.051%w/v; L-proline 0.058%w/v; glycine 0.051%w/v; L-alanine 0.095%w/v; valine 0.139%w/v; methionine 0.085%w/v; isoleucine 0.085%w/v; leucine 0.102%w/v; lysine 0.095%w/v; histidine 0/071%w/v; arginine 0.107%w/v; calcium chloride 0.018%w/v; magnesium chloride 0.005%w/v; sodium chloride 0.538%w/v; sodium s-lactate 0.448%w/v 
Nutrineal PD4 with 1.1% Amino Acids türosiin 0.03%w/v; trüptofaan 0.027%w/v; fenüülalaniin 0.057%w/v; treoniin 0.064%w/v; Lseriin 0.051%w/v; L-proliin 0.058%w/v; glütsiin 0.051%w/v; Lalaniin 0.095%w/v; valiin 0.139%w/v; metioniin 0.085%w/v; isoleutsiin 0.085%w/v; leutsiin 0.102%w/v; lüsiin 0.095%w/v; histidiin 0/071%w/v; arginiin 0.107%w/v; kaltsiumkloriid 0.018%w/v; magnersiumkloriid 0.005%w/v; naatriumkloriid 0.538%w/v; naatrium-s-laktaat 0.448%w/v
Pouet de Camilo 2 
Hispaania Baxter S.L Pouet de Camilo, 2
6.43, Calcium Chloride Dihydrate Ph. Eur. 
6.43, Kaltsiumkloriiddihüdraat Ph. Eur.
Eur., 0.257, Magnesium Chloride Hexahydrate Ph. Eur.0.152, Sodium Lactate Ph. Eur. 
Magneesiumkloriidheksahüdraat Ph. Eur.0.152, Naatriumlaktaat Ph. Eur.
BAXTER d.o.o.,Zelezna cesta 18, 1000 Ljubljana Slovenia 
Bulgaaria BAXTER d.o.o.,Zelezna cesta 18, 1000 Ljubljana, Slovenia
Baxter Healthcare S.A. Moneen Road Castlebar, Co. Mayo Ireland 
Baxter Healthcare S.A. Moneen Road Castlebar, CO. Mayo lreland
0.714 g L-Arginine Ph.Eur. 
0.714 g L-Arginiin Ph.Eur.
Baxter Healthcare Ltd., Caxton Way, Thetford, 
Baxter Healthcare Ltd Caxton Way,